Media Archive
Search our media archive for news, events or related images on your topic.
| Content | |
|---|---|
Foto Bibliothek Herceptin 150 mg vial: medicine used to treat breast cancer more | |
Foto Bibliothek Herceptin, medicine used to treat breast cancer. (Personalized Healthcare, PHC)more | |
Foto Bibliothek Employee in Herceptin production putting on protective clothingmore | |
| 24. September 2009 Herceptin provides impressive survival benefit for patients with high levels of HER2 in their stomach cancer A detailed analysis of the Phase III ToGA study announced today revealed an unprecedented survival benefit for patients whose ... more | |
| 31. Mai 2009 Herceptin landmark study (ToGA) reveals unprecedented survival benefit in HER2-positive stomach cancer Data from the ToGA study presented today at the American Society for Clinical Oncology Annual Meeting in Orlando, Florida ... more | |
| 18. M¿rz 2009 Herceptin now shown to significantly prolong the lives of patients with HER2-positive advanced stomach cancer Roche today announced results from a major international study which show that adding Herceptin (trastuzumab) to standard ... more | |
| 11. M¿rz 2009 Herceptin proven to benefit women with HER2 positive early breast cancer - latest results from the HERA study The Breast International Group (BIG) in collaboration with Roche announced today that women with HER2 positive early breast ... more | |
| 11. Dezember 2008 Herceptin given prior to surgery improves the chance of survival without relapse for women with HER2-positive breast cancer About 70% of women with locally advanced HER2-positive breast cancer were free of their disease three years after initiation ... more | |
| 10. Dezember 2008 New data show that Herceptin, Xeloda and Avastin help patients with early and advanced breast cancer live longer or remain disease free for longer New data being presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) show that Herceptin (trastuzumab), ... more | |
| Mediarelease, 2008/02/29 Herceptin approved in Japan for early treatment in patients with HER2-positive breast cancer Roche announced today that its majority-owned subsidiary Chugai Pharmaceutical Co. Ltd received approval from the Japanese ... more | |
| Mediarelease, 2007/09/26 Herceptin eradicates tumours and may reduce the need for mastectomies in women with inflammatory HER2-positive breast cancer - one of the most aggressive and fastest growing forms of the disease New data show that the addition of Herceptin (trastuzumab) to chemotherapy prior to breast cancer surgery (neoadjuvant therapy) ... more | |
| Mediarelease, 2007/06/04 Investigational cancer drug Pertuzumab shows promising results in advanced breast cancer when combined with Herceptin more | |
| Mediarelease, 2007/05/03 Herceptin approved in Europe for use in combination with an aromatase inhibitor for the treatment of patients with HER2 and hormone receptor-co-positive metastatic breast cancer more | |
| Mediarelease, 2007/03/26 Herceptin receives positive opinion in Europe for use in combination with an aromatase inhibitor for the treatment of patients with HER2- and hormone receptor-positive metastatic breast cancer more | |
| 13. October 2006 Roche files Herceptin plus hormonal therapy for advanced HER2-positive breast cancer with European Authorities more | |
| Mediarelease, 2006/10/02 Patients with HER2-positive breast cancer significantly benefit from addition of Xeloda to Herceptin and Taxotere therapy more | |
| Mediarelease, 2006/10/02 Herceptin added to hormonal therapy increases progression-free survival in patients with advanced HER2-positive breast cancer more | |
| 03. June 2006 New data show impressive survival benefit for Herceptin in early-stage HER2-positive breast cancer more | |
| 29. May 2006 Herceptin added to hormonal therapy prolongs progression-free survival for patients with advanced HER2-positive breast cancer more | |
| 24. May 2006 Herceptin approved in Europe for early use in HER2-positive breast cancer more | |
| 28. April 2006 Herceptin receives positive opinion in Europe for early use in HER2-positive breast cancer more | |
| 17. February 2006 Roche files Herceptin for early-stage HER2-positive breast cancer with European Authorities more | |
| 14. September 2005 New Herceptin results confirm impressive reduction in risk of cancer returning in women with aggressive form of early-stage breast cancer more | |
| 28. April 2005 Herceptin - international study confirms significant improvement in disease-free survival for women with early-stage HER2-positive breast cancer Interim analysis of HERA study based on almost 5,100 patients confirms Herceptin's potential to reduce risk of cancer ... more | |
| 26. April 2005 Herceptin improves survival for the first time in women with early-stage HER2-positive breast cancer Joint interim analysis of two large phase III clinical trials provides first positive data of a targeted therapy after initial ... more | |
| 22. June 2004 European Commission approves Herceptin plus Taxotere as first-line therapy in HER2-positive metastatic breast cancer more | |
| Mediarelease, 2002/05/15 Roche wins patent dispute with Chiron on Herceptin | |
| Mediarelease, 2001/06/01 New hope for thousands of breast cancer patients in Japan: Herceptin launched today | |
| Mediarelease, 2001/04/04 Japan approves breakthrough breast cancer drug Herceptin | |
| Mediarelease, 2001/03/15 New England Journal of Medicine publication confirms Herceptin can improve survival in women with severe breast cancer | |
| Mediarelease, 2000/08/30 Roche Receives EU Approval for Herceptin | |
| Mediarelease, 2000/05/26 European Health Authority (CPMP) Supports Use of Herceptin Therapy in the Treatment of Metastatic Breast Cancer; Approval in Europe Expected Later This Year | |
| Mediarelease, 1999/08/02 Roche receives marketing clearance in first European country for Herceptin® | |
| Mediarelease, 1998/07/06 Roche and Genentech sign Licensing Agreement for Herceptin® |